Zydus Lifesciences Ltd.
ZYDUSLIFE · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹966.21.
Piotroski F-score 2/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%18.3%
- ✓Low debt (D/E < 0.5)0.42x
- ✓Positive free cash flow
- ✓Revenue growth > 10%16%
- ✓Earnings growing9%
- ✓Net margin ≥ 10%18.6%
- ✕Current ratio > 1.51.27
- ✓Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 4.15
- ✕Piotroski ≥ 72/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (18.3%).
- •Healthy profit margin (18.6%).
- •Trading near its 52-week high.
- •Financially solid — Altman Z 4.15.
Weaknesses
- •Weak Piotroski score (2/9).
Opportunities
- •Revenue growing (16% YoY).
- •Trading in our value buy zone versus sector peers.
About Zydus Lifesciences Ltd.
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFre
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.